Premium
F4‐03‐01: DECREASED DEFAULT MODE NETWORK CONNECTIVITY IN ALZHEIMER'S DISEASE PATIENTS WITH DELUSIONS
Author(s) -
Qian Winnie,
Fischer Corinne E.,
Churchill Nathan W.,
Munoz David G.,
Kumar Sanjeev,
Rajji Tarek K.,
Schweizer Tom A.
Publication year - 2018
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2018.06.2872
Subject(s) - default mode network , precuneus , psychology , functional magnetic resonance imaging , audiology , cognition , delusional disorder , resting state fmri , montreal cognitive assessment , delusion , neuroscience , association (psychology) , atrophy , psychiatry , medicine , cognitive impairment , psychosis , psychotherapist
is maintained. The primary hypothesis is that the agitation/aggression domain score on the Neuropsychiatric Inventory (NPI) will decrease more on lithium than placebo. The secondary hypothesis is that there will be a greater number of responders on lithium than placebo. Change in NPI psychosis scores on lithium compared to placebo will be explored. Treatment Emergent Symptom Scale (TESS) scores and emergent adverse events will be used to assess tolerability. Exploratory outcomes include change in serum brainderived neurotrophic factor (BDNF) levels and two genetic markers as potential predictors of response to lithium: a specific SNP on intron 1 of the ACCN1 gene, and variation at the 7q11.2 gene locus. Results:Trial Design; blinded study is in progress. Conclusions:This study will provide initial data on three potential roles for low-dose lithium in clinical practice: (1) first-line treatment; (2) adjunct treatment in partial responders; (3) second-line agent after non-response or intolerability to other medications. The results of this Phase II trial will determine the potential of a large-scale Phase III clinical trial of lithium in these patients.